Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Hormonal Biomarkers and their role in Transcranial magnetic stimulation (TMS) efficacy

EF 2023-24

Résumé
Major Depressive Disorder (MDD) is a chronic condition that affects 20% of the population worldwide, and females are twice as likely to be diagnosed compared to males. Sex and female-specific factors influence health outcomes and disease risk, yet less than 10% of studies examine these factors in psychiatry. Antidepressants alleviate symptoms of depression only in about 35% of people as relief can decline over time. Repetitive transcranial magnetic stimulation (rTMS) is a first line treatment for individuals with MDD that are resistant to standard treatments, however only ~50% of patients benefit from rTMS. Sex differences are seen in rTMS efficacy where females respond more effectively to treatment compared to males, especially during periods of high estradiol. Sex and gender-specific factors such as menopause status, hormonal therapy (menopausal (MHT), gender affirming hormone therapy (GAHT)), pregnancy history, and hormonal contraceptive (HC) use alter both estradiol and inflammatory biomarker levels in females, however, few studies have examined their efficacy on rTMS treatments. The proposed research will examine sex differences as well as these female-specific factors, and our results will provide insights into biomarkers and individual characteristics that improve the efficacy of rTMS treatment in individuals with MDD. Our primary aim is to examine whether female-specific factors (menopause status, HC, pregnancy history) are related to efficacy of rTMS treatment in females and whether inflammatory cytokines are related to treatment efficacy. This knowledge is critical to elucidate mechanisms of response and to aid in the development of personalized approaches to depression treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506267
Name
Splinter Tallinn F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Hormonal Biomarkers and their role in Transcranial magnetic stimulation (TMS) efficacy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cytokines; Estrodiol; Hormonal Contraceptives; Inflammation; Major Depressive Disorder; Menopause; Rtms; Sex Differences; Womens Health
Abstract
Major Depressive Disorder (MDD) is a chronic condition that affects 20% of the population worldwide, and females are twice as likely to be diagnosed compared to males. Sex and female-specific factors influence health outcomes and disease risk, yet less than 10% of studies examine these factors in psychiatry. Antidepressants alleviate symptoms of depression only in about 35% of people as relief can decline over time. Repetitive transcranial magnetic stimulation (rTMS) is a first line treatment for individuals with MDD that are resistant to standard treatments, however only ~50% of patients benefit from rTMS. Sex differences are seen in rTMS efficacy where females respond more effectively to treatment compared to males, especially during periods of high estradiol. Sex and gender-specific factors such as menopause status, hormonal therapy (menopausal (MHT), gender affirming hormone therapy (GAHT)), pregnancy history, and hormonal contraceptive (HC) use alter both estradiol and inflammatory biomarker levels in females, however, few studies have examined their efficacy on rTMS treatments. The proposed research will examine sex differences as well as these female-specific factors, and our results will provide insights into biomarkers and individual characteristics that improve the efficacy of rTMS treatment in individuals with MDD. Our primary aim is to examine whether female-specific factors (menopause status, HC, pregnancy history) are related to efficacy of rTMS treatment in females and whether inflammatory cytokines are related to treatment efficacy. This knowledge is critical to elucidate mechanisms of response and to aid in the development of personalized approaches to depression treatment.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Splinter, Tallinn F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~